Skip to content

Validating the effects of long-term intake of Dr's Lumbricus supplement on serum uric acid levels.

Validating the effects of long-term intake of Dr's Lumbricus supplement on serum uric acid levels. - Validating the effects of long-term intake of Dr's Lumbricus supplement on serum uric acid levels.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000035480
Enrollment
81
Registered
2019-01-11
Start date
2019-02-16
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

Take 4 tablets of Dr&#39
s Lumbricus supplement s.i.d. before meals. Take 4 tablets (2 for Dr&#39
s Lumbricus supplement and 2 for placebo) s.i.d. before meals. Take 4 tablets of placebo s.i.d. before meals.

Sponsors

IMEQRD Co., Ltd
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. 20 to 64 years old (at the time of submission of an informed consent document) 2. Healthy adults (who were judged as healthy individuals by the principal investigator) 3. Men 4. Body mass index (BMI) of less than 30 kg/m2 5. Non-smokers 6. Uric acid levels of 6.0-7.0mg/dl 7. Those who can take supplements for 3 months 8.Those who can provide their written informed consent.

Exclusion criteria

Exclusion criteria: 1. Those who currently need to take medications (except for drugs that are taken as needed) or who need to visit a doctor regularly. 2. Those with one of the following: gouty arthritis, gouty node, and a past medical history of gout attack. 3. Those who have participated in another clinical trial within a month prior to submission of an informed consent document for this trial. 4. Those with a past and current medical history of drug or food allergy. 5. Those who currently take health food (such as food products to maintain or restore health and supplements). 6. Those who were determined by the principal investigator to be unsuitable for participation in this clinical trial.

Design outcomes

Primary

MeasureTime frame
Serum uric acid

Secondary

MeasureTime frame
SF-8(QOL questionnaire)

Countries

Japan

Contacts

Public ContactYoshitada Hira

IMEQRD Co., Ltd Planning and Sales Department

clinical-trial@imeqrd.co.jp03-6704-5968

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026